



Press release

NFL Biosciences strengthens its clinical leadership by expanding Dr. Yannick Plétan's role as Chief Medical Officer as part of the acceleration of its clinical development program for NFL-101 in smoking cessation

Montpellier, France, July 3rd, 2025 at 8:30 am CEST - NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALFNL), a biopharmaceutical company developing innovative botanical medicines for the treatment of addiction, today announced the strengthening of its organization by expanding Dr. Yannick Plétan's role as Chief Medical Officer.

This expanded role supports the accelerated clinical and regulatory development of NFL-101, NFL Biosciences' first-in-class treatment for smoking cessation, as the company prepares to launch the Phase 3 study that will validate its potential in smoking cessation.

A medical consultant for NFL Biosciences since 2018 and a member of the Board of Directors, Dr. Yannick Plétan will continue to act in a consulting capacity as Chief Medical Officer. This expanded role formalizes and strengthens his contribution on an as-needed basis, without significantly increasing operating costs.

With degrees in pulmonology, immunology, clinical pharmacology and pharmacokinetics - post-doctorate at INSERM and visiting professor at the University of California Davis - Dr. Yannick Plétan worked in hospitals for many years before joining the pharmaceutical industry. For 20 years, he held senior positions in the R&D and medical affairs departments of leading laboratories such as Sanofi, Institut de Recherche Pierre Fabre, Pfizer and Roche-Genentech. He played a central role in the creation and worldwide development of the nicotine patch, and in the final development and launch of Champix®.

"We are delighted to strengthen our relationship with a pharmaceutical industry expert like Dr. Yannick Plétan. His expertise and in-depth knowledge of clinical development and medical treatments for smoking cessation will be key to the successful completion of NFL-101's development. Dr. Plétan considerably strengthens our medical and regulatory capabilities at a pivotal moment in the development of NFL-101," **commented Bruno Lafont, Chief Executive Officer of NFL Biosciences.**

"Smoking cessation remains a major public health issue for which few innovative, side-effect-free solutions have emerged in recent years. NFL-101 stands out for its unrivalled safety and efficacy profile. I am delighted to be part of NFL Biosciences at such an important time in the development of this treatment, and am convinced of its potential to become a reference option in the fight against tobacco addiction," **added Dr. Yannick Plétan.**

About NFL Biosciences : www.nflbiosciences.com

NFL Biosciences is a biopharmaceutical company based in the Montpellier region of France, developing plant-based drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, safer and more effective natural therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, NFL-101, is a standardized tobacco leaf extract protected by three patent families. NFL Biosciences intends to offer smokers wishing to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders.

NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 - ALNFL). The company is qualified as an "Innovative Company" eligible for FCPI investment. More information on www.nflbiosciences.com

Contacts :

NewCap

Relations Investisseurs / Relations Médias

Mathilde Bohin / Arthur Rouillé

Tel. : 01 44 71 94 94

E-mail : nfl@newcap.eu

NFL Biosciences

Bruno Lafont

Tél. : 04 11 93 76 67

E-mail : info@nflbiosciences.com